TearLab (TEAR) vs. Antares Pharma (ATRS) Head to Head Analysis

Share on StockTwits

TearLab (OTCMKTS:TEAR) and Antares Pharma (NASDAQ:ATRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of recent ratings for TearLab and Antares Pharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TearLab 0 0 0 0 N/A
Antares Pharma 0 0 3 1 3.25

Antares Pharma has a consensus target price of $5.44, indicating a potential upside of 72.62%. Given Antares Pharma’s higher possible upside, analysts clearly believe Antares Pharma is more favorable than TearLab.

Risk and Volatility

TearLab has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.

Profitability

This table compares TearLab and Antares Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TearLab -22.03% N/A -38.48%
Antares Pharma -27.84% -59.08% -22.25%

Earnings & Valuation

This table compares TearLab and Antares Pharma’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TearLab $27.12 million 0.03 -$16.10 million N/A N/A
Antares Pharma $54.51 million 9.10 -$16.74 million ($0.11) -28.64

TearLab has higher earnings, but lower revenue than Antares Pharma.

Insider & Institutional Ownership

37.4% of Antares Pharma shares are owned by institutional investors. 5.2% of TearLab shares are owned by company insiders. Comparatively, 12.2% of Antares Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Antares Pharma beats TearLab on 8 of the 12 factors compared between the two stocks.

About TearLab

TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.

About Antares Pharma

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector II needle-free auto injectors to administer human growth hormone for patients with growth retardation; and VIBEX disposable pressure-assisted auto injectors. In addition, the company develops XYOSTED for the treatment of testosterone deficiency in adult males; VIBEX auto injectors for treating anaphylaxis; and disposable pen injectors for diabetes and osteoporosis. It has strategic alliances with Teva Pharmaceutical Industries, Ltd. and AMAG Pharmaceuticals, Inc., as well as a development agreement with Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.

Receive News & Ratings for TearLab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply